Quoin Pharmaceuticals Submits QRX003 for Orphan Drug Designation and Fast Track Review in Japan

Reuters

01/28

<a href="https://laohu8.com/S/QNRX">Quoin Pharmaceuticals</a> Submits QRX003 for Orphan Drug Designation and <a href="https://laohu8.com/S/FTRK">Fast Track</a> Review in Japan

Quoin Pharmaceuticals Ltd. announced that it has submitted an application for Orphan Drug Designation $(ODD)$ for its lead product candidate, QRX003, for the treatment of Netherton Syndrome to the Japanese Ministry of Health, Labour and Welfare (MHLW). The MHLW has confirmed that QRX003 qualifies for both Orphan Drug Designation and Fast Track regulatory review status in Japan. QRX003 previously received Orphan Drug Designation from the U.S. Food and Drug Administration and the European Medicines Agency in 2025. If granted in Japan, QRX003 will have ODD status in Quoin's key commercial territories of the US, EU, and Japan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9642807) on January 27, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2606731248"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2606731248\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2606731248?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-28 01:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606731248","market":"fut","top_or_hot":-1,"title":"Quoin Pharmaceuticals Submits QRX003 for Orphan Drug Designation and Fast Track Review in Japan","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/QNRX\">Quoin Pharmaceuticals</a> Submits QRX003 for Orphan Drug Designation and <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Review in Japan\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quoin Pharmaceuticals Ltd. announced that it has submitted an application for Orphan Drug Designation <a href=\"https://laohu8.com/S/ODD\">$(ODD)$</a> for its lead product candidate, QRX003, for the treatment of Netherton Syndrome to the Japanese Ministry of Health, Labour and Welfare (MHLW). The MHLW has confirmed that QRX003 qualifies for both Orphan Drug Designation and Fast Track regulatory review status in Japan. QRX003 previously received Orphan Drug Designation from the U.S. Food and Drug Administration and the European Medicines Agency in 2025. If granted in Japan, QRX003 will have ODD status in Quoin's key commercial territories of the US, EU, and Japan.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9642807) on January 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quoin Pharmaceuticals Submits QRX003 for Orphan Drug Designation and Fast Track Review in Japan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuoin Pharmaceuticals Submits QRX003 for Orphan Drug Designation and Fast Track Review in Japan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-28 01:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/QNRX\">Quoin Pharmaceuticals</a> Submits QRX003 for Orphan Drug Designation and <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Review in Japan\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quoin Pharmaceuticals Ltd. announced that it has submitted an application for Orphan Drug Designation <a href=\"https://laohu8.com/S/ODD\">$(ODD)$</a> for its lead product candidate, QRX003, for the treatment of Netherton Syndrome to the Japanese Ministry of Health, Labour and Welfare (MHLW). The MHLW has confirmed that QRX003 qualifies for both Orphan Drug Designation and Fast Track regulatory review status in Japan. QRX003 previously received Orphan Drug Designation from the U.S. Food and Drug Administration and the European Medicines Agency in 2025. If granted in Japan, QRX003 will have ODD status in Quoin's key commercial territories of the US, EU, and Japan.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9642807) on January 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDL9ZFPWQ:1","article_id":"2606731248","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606731248","pubTimestamp":1769535858,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Quoin Pharmaceuticals Ltd. announced that it has submitted an application for Orphan Drug Designation  for its lead product candidate, QRX003, for the treatment of Netherton Syndrome to the Japanese Ministry of Health, Labour and Welfare . The MHLW has confirmed that QRX003 qualifies for both Orphan Drug Designation and Fast Track regulatory review status in Japan. QRX003 previously received Orphan Drug Designation from the U.S. Food and Drug Administration and the European Medicines Agency in 2025. If granted in Japan, QRX003 will have ODD status in Quoin's key commercial territories of the US, EU, and Japan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","BK4139":"生物科技","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","QNRX":"Quoin Pharmaceuticals"},"translate_title":"Quoin Pharmaceuticals在日本提交QRX003孤儿药认定和快速通道审评","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QNRX":0.9,"NDAQ":0.9},"content_text":"Quoin Pharmaceuticals Submits QRX003 for Orphan Drug Designation and Fast Track Review in Japan\n    \n\n        Quoin Pharmaceuticals Ltd. announced that it has submitted an application for Orphan Drug Designation $(ODD)$ for its lead product candidate, QRX003, for the treatment of Netherton Syndrome to the Japanese Ministry of Health, Labour and Welfare (MHLW). The MHLW has confirmed that QRX003 qualifies for both Orphan Drug Designation and Fast Track regulatory review status in Japan. QRX003 previously received Orphan Drug Designation from the U.S. Food and Drug Administration and the European Medicines Agency in 2025. If granted in Japan, QRX003 will have ODD status in Quoin's key commercial territories of the US, EU, and Japan.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9642807) on January 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}